Protagenic Therapeutics, Inc. (PTIX)
1.026
-0.03
(-3.22%)
USD |
OTCM |
Sep 08, 16:00
Protagenic Therapeutics EPS Diluted (Quarterly) : -0.5323 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5323 |
| March 31, 2026 | 2.809 |
| December 31, 2025 | 1.143 |
| September 30, 2025 | -0.4702 |
| June 30, 2025 | -1.366 |
| March 31, 2025 | -2.752 |
| December 31, 2024 | -3.346 |
| September 30, 2024 | -0.1415 |
| June 30, 2024 | -0.3616 |
| March 31, 2024 | -0.3888 |
| December 31, 2023 | -0.3829 |
| September 30, 2023 | -0.3225 |
| June 30, 2023 | -0.2793 |
| March 31, 2023 | -0.1663 |
| December 31, 2022 | -0.1392 |
| September 30, 2022 | -0.2141 |
| June 30, 2022 | -0.1543 |
| March 31, 2022 | -0.3162 |
| December 31, 2021 | -0.207 |
| September 30, 2021 | -0.2126 |
| June 30, 2021 | -0.4272 |
| March 31, 2021 | -0.4585 |
| December 31, 2020 | -0.2022 |
| September 30, 2020 | -0.4069 |
| June 30, 2020 | -0.2207 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.1944 |
| December 31, 2019 | -0.2923 |
| September 30, 2019 | -0.0481 |
| June 30, 2019 | -0.1086 |
| March 31, 2019 | -0.2336 |
| December 31, 2018 | -0.3078 |
| September 30, 2018 | -0.1939 |
| June 30, 2018 | -0.28 |
| March 31, 2018 | -0.24 |
| December 31, 2017 | -0.28 |
| September 30, 2017 | -0.16 |
| June 30, 2017 | -0.16 |
| March 31, 2017 | -0.24 |
| December 31, 2016 | -0.2168 |
| September 30, 2016 | -0.24 |
| June 30, 2016 | -55.67 |
| March 31, 2016 | -211.55 |
| June 30, 2015 | -17.32 |
| March 31, 2015 | -18.56 |
| December 31, 2014 | -20.41 |
| September 30, 2011 | -44536.32 |
| June 30, 2011 | -60000.32 |
| March 31, 2011 | -34639.36 |
| December 31, 2010 | -82268.48 |
| September 30, 2010 | -42062.08 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0749 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.9636M |
| Total Expenses (Quarterly) | 0.9636M |
| Enterprise Value | 1.291M |
| Earnings Yield | 287.4% |
| Normalized Earnings Yield | 200.52 |